title: Anti-JC-virus antibody prevalence in a German MS cohort.
authors: Clemens
authors: C
authors: Warnke
authors: Thomas
authors: T
authors: Dehmel
authors: Anita
authors: A
authors: Posevitz-Fejfár
authors: Andrew
authors: A
authors: Chan
authors: Achim
authors: A
authors: Berthele
authors: Stephan
authors: S
authors: Schmidt
authors: Judith
authors: J
authors: Haas
authors: Helena C
authors: HC
authors: Kronsbein
authors: Florian
authors: F
authors: Seitz
authors: Björn
authors: B
authors: Tackenberg
authors: Mathias
authors: M
authors: Mäurer
authors: Kathrin
authors: K
authors: Gerbershagen
authors: Volker
authors: V
authors: Limmroth
authors: Ortwin
authors: O
authors: Adams
authors: Hans-Peter
authors: HP
authors: Hartung
authors: Ralf
authors: R
authors: Gold
authors: Bernhard
authors: B
authors: Hemmer
authors: Heinz
authors: H
authors: Wiendl
authors: Bernd C
authors: BC
authors: Kieseier
mesh_terms: D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D000914:Antibodies, Viral / Q000032:analysis*; D002648:Child; D015331:Cohort Studies; D005260:Female; D005858:Germany; D006801:Humans; D007577:JC Virus / Q000276:immunology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D000069442:Natalizumab; D027601:Polyomavirus Infections / Q000150:complications / Q000453:epidemiology*; D015995:Prevalence; D012307:Risk Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000914:Antibodies, Viral; D000069442:Natalizumab